A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous and Nivolumab Subcutaneous Versus Nivolumab Intravenous in Participants With Melanoma
Latest Information Update: 17 Apr 2025
At a glance
- Drugs Hyaluronidase (Primary) ; Nivolumab (Primary) ; Nivolumab/relatlimab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 06 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 13 Dec 2023 Status changed from not yet recruiting to recruiting.